Cibc World Markets Corp Takes $39,000 Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Cibc World Markets Corp bought a new position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 17,683 shares of the biopharmaceutical company’s stock, valued at approximately $39,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Intech Investment Management LLC acquired a new position in Esperion Therapeutics in the third quarter worth approximately $94,000. BNP Paribas Financial Markets boosted its stake in shares of Esperion Therapeutics by 152.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 123,333 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 74,522 shares in the last quarter. MetLife Investment Management LLC grew its holdings in shares of Esperion Therapeutics by 47.1% in the 3rd quarter. MetLife Investment Management LLC now owns 71,050 shares of the biopharmaceutical company’s stock worth $117,000 after acquiring an additional 22,734 shares during the last quarter. Wasatch Advisors LP raised its position in shares of Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after purchasing an additional 6,483,070 shares during the period. Finally, State Street Corp lifted its holdings in shares of Esperion Therapeutics by 2.7% during the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after purchasing an additional 99,802 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Stock Performance

Shares of ESPR opened at $1.50 on Friday. The company has a market capitalization of $296.77 million, a PE ratio of -2.34 and a beta of 1.04. The company’s 50 day moving average price is $1.78 and its 200 day moving average price is $2.07. Esperion Therapeutics, Inc. has a 52 week low of $1.47 and a 52 week high of $3.94.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ESPR shares. Cantor Fitzgerald started coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Thursday, March 20th. JMP Securities restated a “market outperform” rating and issued a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $6.75.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.